Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibiotic-combination fecal microbiota transplantation for active ulcerative colitis
jRCTs031260318Recruiting
- Sponsor
- Metagen Therapeutics, Inc.
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of amoxicillin, fosfomycin and metronidazole in autoimmune colitis (2 arms), sponsored by Metagen Therapeutics, Inc. Primary endpoint: Remission rate at 8 weeks after initiation of FMT treatment. Started Sep 2026; status: recruiting.
02
Drugs
amoxicillinfosfomycinmetronidazole
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCTs031260318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031260318.